



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)

(Stock code 股份代號：9989)

NOTIFICATION LETTER 通知信函

Dear Non-Registered Shareholder ^(Note 1),

December 18, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company")

– Notice of publication of Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications")

The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.hepalink.com and the HKExnews' website at www.hkexnews.hk. You may access the Current Corporate Communications by selecting the relevant document(s) under "Investor's Information" on the Company's website or browsing through the HKExnews' website.

If you wish to receive the printed copies of the Current Corporate Communications and all future Corporate Communications ^(Note 2) of the Company, please complete the request form (the "Request Form") (which may also be downloaded from the websites mentioned above) on the back of this Letter and return it to the Company (c/o Tricor Investor Services Limited (the "Hong Kong Share Registrar")) by using the pre-paid mailing label at the bottom of the Request Form (if posted in Hong Kong). Otherwise, please affix sufficient postage. The address of the Hong Kong Share Registrar is 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

Upon receipt of your request, the Company will promptly send you the printed copy of the Current Corporate Communications free of charge.

Should you have any queries relating to any of the above matters, please call the customer service hotline of the Hong Kong Share Registrar at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Note 1: This letter is being sent to the non-registered holders of the shares of the Company, whose shares are held in the Central Clearing and Settlement System (CCASS) and who have notified the Company through Hong Kong Securities Clearing Company Limited that they wish to receive the Company's Corporate Communications. If you have sold or transferred all your shares in the Company, please disregard this letter and the Request Form on the back of this Letter.

Note 2: Corporate Communications (the "Corporate Communications") of the Company refers to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the annual report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

致非登記股份持有人 ^(附註1)：

深圳市海普瑞藥業集團股份有限公司 (「本公司」)

—2024年第一次臨時股東大會通函、通告及代表委任表格 (「本次公司通訊文件」) 之發佈通知

本公司的本次公司通訊文件中，英文版本現已上載於本公司網站 www.hepalink.com 及香港交易所披露易網站 www.hkexnews.hk，歡迎瀏覽。請在本公司網站主頁的「投資者專區」項下選擇有關文件或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊文件 ^(附註2) 之印刷本，請填妥在本信函背面的申請表格 (「申請表格」) (該表格亦可於上述網站下載)，並使用申請表格下方的預付費郵寄標籤寄回 (如在香港投寄)；否則，請貼上足夠的郵票。申請表格請經卓佳證券登記有限公司 (「香港股份登記處」) 寄回本公司，香港股份登記處的地址為香港夏愨道16號遠東金融中心17樓。

閣下提出要求後立即免費向閣下寄上本次公司通訊文件的印刷版本。

如閣下對本信函內容有任何疑問，請於星期一至五 (公眾假期除外) 上午九時正至下午六時正期間致電香港股份登記處的客戶服務電話查詢熱線 (852) 2980 1333。

代表
深圳市海普瑞藥業集團股份有限公司
董事長
李鋁
謹啟

2023年12月18日

附註1：本信函收件對象為本公司非登記股份持有人。該等人士的股份存放於中央結算及交收系統 (中央結算系統)，並且他們已經通過香港中央結算有限公司通知本公司，希望收到本公司公司通訊文件。如果閣下已出售或轉讓全部所持有的本公司股份，則無需要理會本信函及其背面的申請表格。

附註2：本公司公司通訊文件 (「公司通訊文件」) 指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a) 年度報告及財務摘要報告 (如適用)；(b) 中期報告及中期摘要報告 (如適用)；(c) 會議通告；(d) 上市文件；(e) 通函；及 (f) 委任代表表格。

Request Form 申請表格

To: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
(the "Company")
(Stock Code: 9989)
c/o Tricor Investor Services Limited
(the "Hong Kong Share Registrar")
17/F, Far East Finance Centre,
16 Harcourt Road, Hong Kong

致：深圳市海普瑞藥業集團股份有限公司
(「本公司」)
(股份代號：9989)
經卓佳證券登記有限公司
(「香港股份登記處」)
香港夏愨道16號
遠東金融中心17樓

I/We would like to receive the Current Corporate Communications* and all future Corporate Communications** of the Company in the manner as indicated below:

本人／我們現在希望以下列方式收取本公司本次*及將來**所有公司通訊文件：

(Please mark **ONLY ONE (X)** of the following boxes) (請從下列選擇中，僅在其中一個空格內劃上「X」號)

- to receive printed copies of notification letters only informing that the Corporate Communications (including the Current Corporate Communications) have been published on the Company's website www.hepalink.com but not the printed copies of the same ^(Note 2); OR
僅收取有關公司通訊文件已在本公司網站www.hepalink.com刊發之通知信函並在本公司網站上瀏覽公司通訊文件(包括本次公司通訊文件)，而非印刷本^(附註2)；或
- to receive the printed copies of all Corporate Communications (including the Current Corporate Communications) in both English and Chinese versions; OR
收取所有公司通訊文件之中、英文印刷本(包括本次公司通訊文件)；或
- to receive the printed copies of all Corporate Communications (including the Current Corporate Communications) in English version only; OR
僅收取所有公司通訊文件之英文印刷本(包括本次公司通訊文件)；或
- to receive the printed copies of all Corporate Communications (including the Current Corporate Communications) in Chinese version only.
僅收取所有公司通訊文件之中文印刷本(包括本次公司通訊文件)。

Name(s) of Non-registered Holder(s)[#]
非登記持有人姓名[#]

Signature
簽名

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Address[#]
地址[#]

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Contact telephone number
聯絡電話號碼

Date
日期

[#] You are required to fill in the details if you download this Request Form from the Company's website or the HKEnews' website.
假如你從本公司網站或香港交易所披露易網站下載本申請表格，請必須填上有關資料。

Notes 附註：

- Please complete all your details clearly.
請閣下清楚填妥所有資料。
 - By electing this option, you have expressly consented to waive the right to receive the Corporate Communications in printed form.
在選擇本項後，閣下已明示同意放棄收取公司通訊文件印刷本的權利。
 - This Request Form is to be completed by the non-registered holders of the shares of the Company, whose shares are held in the Central Clearing and Settlement System (CCASS) and who have notified the Company through Hong Kong Securities Clearing Company Limited that they wish to receive the Company's Corporate Communications.
本申請表格應由本公司非登記股份持有人填寫。該等人士的股份存放於中央結算及交收系統(中央結算系統)，並且他們已經通過香港中央結算有限公司通知本公司，希望收到本公司公司通訊文件。
 - Any Request Form with more than one box marked (X), with no box marked (X), bearing no signature or otherwise incorrectly completed shall be void.
如在申請表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確，則有關表格將會作廢。
 - For the avoidance of doubt, the Company does not accept any other instructions given on this Form. Any other instructions inserted on this Form will be void.
為免存疑，本公司恕不接受此表格上提供的任何其他指示。任何在此表格上提供的額外指示將視作無效。
 - You are entitled to change the choice of language or means of receipt of the Company's Corporate Communications at any time by reasonable notice in writing to the Company (c/o the Hong Kong Share Registrar).
閣下有權隨時發出合理時間的書面通知通過香港股份登記處予本公司，要求更改本公司公司通訊文件之語言版本或收取方式。
- * The Current Corporate Communications of the Company refer to the Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting.
本公司本次公司通訊文件指2024年第一次臨時股東大會通函、通告及代表委任表格。
- ** The Corporate Communications of the Company refers to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the annual report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
本公司公司通訊文件指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a) 年度報告及財務摘要報告(如適用)；(b) 中期報告及中期摘要報告(如適用)；(c) 會議通告；(d) 上市文件；(e) 通函；及(f) 委任代表表格。



Please cut the mailing label and stick it on an envelope
to return this Request Form to us.
No postage is necessary if posted in Hong Kong.

當閣下寄回本申請表格時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。

Mailing Label 郵寄標籤

Tricor Investor Services Limited
卓佳證券登記有限公司
Freepost No. 簡便回郵號碼：10 GPO
Hong Kong 香港